SCHEMBL4937083

SCHEMBL4937083

COC(C)(C)CCC(C)=O

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
GAA P10253 2/20 0.39
TDP1 Q9NUW8 3/20 0.38
TSHR P16473 2/20 0.38
LMNA P02545 2/20 0.36
SLC15A2 Q16348 1/20 0.36
MGAM O43451 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
CYP3A4 P08684 1/20 0.33
ACHE P22303 1/20 0.31
PAOX Q6QHF9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24157932 0.88 ALDH1A1 (0.33) ALDH1A1GAATDP1TSHR
SCHEMBL11232780 0.86 ALDH1A1 (0.39) ALDH1A1GAATDP1TSHRLMNA
SCHEMBL12561149 0.82 KDM4E (0.45) ALDH1A1GAATDP1TSHRLMNA
SCHEMBL12301948 0.81 ALDH1A1 (0.35) ALDH1A1GAATDP1TSHRLMNA
SCHEMBL12410508 0.80 NAALAD2 (0.43) ALDH1A1TDP1TSHRLMNASLC15A2
SCHEMBL4847615 0.80 ALDH1A1 (0.43) ALDH1A1GAATDP1TSHRLMNA
SCHEMBL17445680 0.78 TSHR (0.36) ALDH1A1TDP1TSHR
SCHEMBL12602055 0.78 TSHR (0.55) ALDH1A1GAATDP1TSHRLMNA
SCHEMBL9868805 0.76 ALDH1A1 (0.35) ALDH1A1TDP1TSHR
SCHEMBL9868811 0.76 ALDH1A1 (0.35) ALDH1A1TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160016903-A1 Substituted Azaspiro(4.5)Decane Derivatives GRUENENTHAL GMBH (DE) 2016-01-21 US disclosed
WO-2016008583-A1 SUBSTITUTED AZA-SPIRO(4.5)DECAN-DERIVATIVES Grünenthal GmbH (DE) 2016-01-21 WO disclosed
US-20110152259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF PALANI ANANDAN 2011-06-23 US disclosed
US-20080182994-A1 Crystal of 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid and process for producing the same TAKEDA PHARMACEUTICAL COMPANY LIMITED 2008-07-31 US disclosed
US-20060205801-A1 Crystal and process for producing the same HASHIMOTO HIDEO 2006-09-14 US disclosed
US-7067546-B2 Crystal and process for producing the same TAKEDA PHARMACEUTICAL COMPANY (JP) 2006-06-27 US disclosed
US-20040215023-A1 Crystal and process for producing the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-10-28 US disclosed
EP-1420016-A1 CRYSTAL AND PROCESS FOR PRODUCING THE SAME Takeda Chemical Industries, Ltd. (JP) 2004-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205801-A1 Crystal and process for producing the same RCC1, RCC2, NPM1 ALDH1A1 1641/4885GAA 3606/4885TDP1 2560/4885
US-20080182994-A1 Crystal of 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid and process for producing the same BRD7, BMI1, ALK ALDH1A1 800/4885GAA 3360/4885TDP1 2486/4885
US-20160016903-A1 Substituted Azaspiro(4.5)Decane Derivatives OPRL1, OPRD1, OPRM1 ALDH1A1 386/4885GAA 4184/4885TDP1 4479/4885
US-20110152259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF CYP11B2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B1 ALDH1A1 1177/4885GAA 1668/4885TDP1 1414/4885
US-20040215023-A1 Crystal and process for producing the same SBDS, RCC1, RCC2 ALDH1A1 1224/4885GAA 2693/4885TDP1 3385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.